Equities

Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.15
  • Today's Change0.00 / 0.00%
  • Shares traded2.43m
  • 1 Year change+94.44%
  • Beta1.8074
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments72122102
Total Receivables, Net393117
Total Inventory392518
Prepaid expenses5.789.294.59
Other current assets, total------
Total current assets156187143
Property, plant & equipment, net299.516.63
Goodwill, net232323
Intangibles, net110121131
Long term investments------
Note receivable - long term------
Other long term assets4.544.730.83
Total assets323345304
LIABILITIES
Accounts payable124.618.92
Accrued expenses636668
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total202.661.99
Total current liabilities957479
Total long term debt19118788
Total debt19118788
Deferred income tax2.273.524.94
Minority interest------
Other liabilities, total413537
Total liabilities329299209
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital610600555
Retained earnings (accumulated deficit)(617)(555)(460)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.03)(0.02)(0.03)
Total equity(6.78)4595
Total liabilities & shareholders' equity323345304
Total common shares outstanding138136125
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.